Let's Talk About
Desire.
PT-141, also known as bremelanotide, is a melanocortin receptor agonist. The FDA-approved drug Vyleesi is indicated for a specific sexual health condition called acquired, generalized hypoactive sexual desire disorder in premenopausal women.
PT-141 has a very specific
place in sexual health.
PT-141 is the common name used for bremelanotide, a melanocortin receptor agonist.
Bremelanotide works through melanocortin receptors in the central nervous system. Unlike medications that primarily affect blood flow, bremelanotide acts on neural pathways involved in sexual desire.
The FDA-approved product Vyleesi is indicated for acquired, generalized HSDD in premenopausal women. That means the condition involves low sexual desire that causes significant distress or interpersonal difficulty and is not explained by another medical or psychiatric condition, relationship problems, or a medication or drug substance.
Think Of It
Like This.
One of the easiest ways to understand PT-141 is to separate two concepts people often mix together: desire and performance.
The Interest
This refers to sexual desire or interest — the motivation or inclination toward sexual activity.
The Pathway
Bremelanotide acts on melanocortin receptors and affects neural pathways associated with sexual desire.
Desire?
Performance?
Choose the statement that sounds closest to your concern. This is simply an educational starting point — not a diagnosis.
Could It Be HSDD?
If low sexual desire is persistent, acquired, generalized and causing significant personal distress or interpersonal difficulty, a healthcare provider can evaluate whether HSDD may be involved and whether treatment options such as bremelanotide are appropriate.
That's A Different Conversation.
PT-141 should not simply be marketed as a sexual performance enhancer. The FDA-approved indication for bremelanotide is acquired, generalized HSDD in premenopausal women. A provider can help determine what may be contributing to a performance concern.
You Don't Have To Know.
Changes in sexual desire can have many potential contributors, including medications, medical conditions, mental health, hormones, stress and relationship factors. A consultation is a place to start understanding what's going on.
The right treatment starts
with the right evaluation.
Bremelanotide is not appropriate for everyone. The FDA-approved indication is specifically for premenopausal women with acquired, generalized HSDD.
Before treatment, your provider should consider your medical history, medications, cardiovascular risk and the potential causes of changes in sexual desire.
A Change In Desire
The condition is acquired, meaning the low desire developed after a period without the problem.
Generalized
The low desire occurs across situations, types of stimulation or partners rather than only in one specific circumstance.
Causes Matter
A provider should consider whether medications, medical conditions, psychiatric conditions or relationship factors may explain the concern.
Distress Matters
HSDD involves low desire that causes marked personal distress or interpersonal difficulty.
Understanding the treatment
means understanding the risks.
Bremelanotide can temporarily increase blood pressure and decrease heart rate after a dose. Blood pressure typically returns toward baseline within several hours.
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. It is also not recommended for patients at high risk for cardiovascular disease.
Nausea is the most commonly reported adverse reaction with Vyleesi. Other potential adverse effects include flushing, injection-site reactions, headache and vomiting.
One More Thing To Know
Focal hyperpigmentation can occur, including on the face, gums and breasts. The FDA labeling notes that patients with darker skin were more likely to develop focal hyperpigmentation in clinical studies.
What Happens Next?
Private Conversation
Tell your provider what has changed and what you're hoping to address.
Medical Review
Your provider reviews your health history, medications and cardiovascular risk factors.
Determine Appropriateness
The provider determines whether bremelanotide is appropriate and whether another approach makes more sense.
Informed Decision
You should understand potential benefits, risks, limitations and alternatives before treatment.
PT-141
Pricing shown for our PT-141 offering. Eligibility, formulation, route of administration and treatment plan are determined by the provider.
BOOK A CONSULTATIONYour Questions, Answered.
What is PT-141?
What is PT-141 used for?
Is PT-141 the same as bremelanotide?
Is PT-141 FDA approved?
Is PT-141 a libido booster?
Who should not use bremelanotide?
Can PT-141 improve sexual performance?
You Don't Have To
Figure It Out Alone.
If something has changed, let's start with a conversation about what's actually going on.
BOOK A CONSULTATION